Processing

Please wait...

Settings

Settings

1. WO1996003130 - USE OF A PROGESTERONE ANTAGONIST AND OF A GESTAGEN FOR THE TREATMENT OF ENDOMETRIOSIS OR LEIOMYOMATA UTERI

Publication Number WO/1996/003130
Publication Date 08.02.1996
International Application No. PCT/EP1995/002998
International Filing Date 27.07.1995
Chapter 2 Demand Filed 25.02.1996
IPC
A61K 31/565 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
565not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/57 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
57substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
CPC
A61K 31/565
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
565not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
A61K 31/57
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
57substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
A61P 13/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
02of urine or of the urinary tract, e.g. urine acidifiers
A61P 15/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders
Applicants
  • SCHERING AKTIENGESELLSCHAFT [DE/DE]; Müllerstrasse 178 D-13353 Berlin, DE (AllExceptUS)
  • STÖCKEMANN, Klaus [DE/DE]; DE (UsOnly)
  • CHWALISZ, Kristof [DE/DE]; DE (UsOnly)
Inventors
  • STÖCKEMANN, Klaus; DE
  • CHWALISZ, Kristof; DE
Priority Data
P 44 26 601.427.07.1994DE
Publication Language German (DE)
Filing Language German (DE)
Designated States
Title
(DE) PROGESTERONANTAGONIST UND GESTAGEN ZUR BEHANDLUNG DER ENDOMETRIOSE UND LEIOMYOMATA UTERI
(EN) USE OF A PROGESTERONE ANTAGONIST AND OF A GESTAGEN FOR THE TREATMENT OF ENDOMETRIOSIS OR LEIOMYOMATA UTERI
(FR) UTILISATION D'UN ANTAGONISTE DE PROGESTERONE ET D'UN PROGESTATIF POUR LE TRAITEMENT DE L'ENDOMETRIOSE OU DES FIBROMIOMES UTERINS
Abstract
(DE)
Die vorliegende Erfindung betrifft die Verwendung eines Produkts, enthaltend in Kombination einzelne Dosierungseinheiten eines kompetitiven Progesteronantagonisten und einzelne Dosierungseinheiten eines Gestagens zu dessen sequentieller, oraler Verabreichung, worin jede einzelne, den kompetitiven Progesteronantagonisten enthaltende Dosierungseinheit, diesen in einer nicht-abortauslösenden Menge enthält, zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des $i(Leiomyomata uteri).
(EN)
The present invention concerns the use of a product containing in combination individual dosage units of a competitive progesterone antagonist and individual dosage units of a gestagen to be sequentially orally administrated (the competitive progesterone antagonist being present in each individual dosage unit in quantities not capable of inducing miscarriage) to produce a medicament for use in the treatment of endometriosis or $i(leiomyomata uteri).
(FR)
La présente invention concerne l'utilisation d'un produit contenant, en combinaison, des unités de dosage individuelles d'un antagoniste compétitif de progestérone et des unités de dosage individuelles d'un progestatif à administrer par voie orale, de façon séquentielle (l'antagoniste compétitif de progestérone étant présent dans chaque unité de dosage individuelle en une quantité ne pouvant pas induire un avortement) pour produire un médicament destiné à être utilisé dans le traitement de l'endométriose ou des fibromiomes utérins.
Also published as
CZPV1997-207
FI970260
IS4407
NO19970309
NZ291417
SK10497
SK199700104
Other related publications
Latest bibliographic data on file with the International Bureau